Available to hire
Biotech and life sciences strategy & translational development leader with 20+ years of global experience across translational program development, portfolio strategy, and cross-functional program leadership. Proven ability to translate complex scientific, operational, and competitive data into actionable insights for portfolio prioritization, investment evaluation, and executive decision-making.
Currently advising innovation-driven organizations and investors through Biovertex Consulting, supporting translational strategy, portfolio prioritization, INDiC-enabling planning, and commercialization readiness for early-stage therapeutic programs. Previously led portfolio program management and alliance management at Tessa Therapeutics, building standardized dashboards and governance frameworks to improve operational efficiency, reduce redundancy, and strengthen risk/timeline transparency across multiple programs.
Experience Level
Expert
Expert
Expert
Intermediate
Intermediate
Language
English
Advanced
Work Experience
Founder at Biovertex Consulting LLP
March 1, 2025 - PresentAdvised innovation-driven organizations and investors on translational strategy, portfolio prioritization, INDiC-enabling planning, and commercialization readiness for early-stage therapeutic programs. Conducted venture evaluation and investment diligence activities via strategic assessment of development feasibility, execution risk, milestone planning, and clinical/regulatory pathways. Supported emerging ventures through ecosystem engagement, strategic positioning, stakeholder communication, and growth planning.
Director, Portfolio Program & Alliance Management at Tessera Therapeutics, USA
January 1, 2024 - July 31, 2024Built standardized portfolio dashboards and reporting systems integrating scientific and operational data to enable visibility into program risks, timelines, and resource allocation. Led the program management function by implementing stage-appropriate tools and frameworks to improve operational efficiency and reduce redundancy across four portfolio programs.
Associate Director, Program Management & Portfolio Strategy / Operations at Tessera Therapeutics, USA
July 1, 2022 - December 31, 2023Co-led preclinical programs for rare genetic liver disorders, developing, managing, and tracking integrated plans spanning goals, risk management, and timelines from target ideation through first-in-human trial initiation. Partnered with non-clinical, CMC, clinical, and regulatory leads to develop integrated program strategies, risk assessments, and cross-functional execution plans. Facilitated program and governance meetings by structuring agendas, guiding discussions, challenging assumptions, and enabling data-driven decision-making using DACI/RACI frameworks. Established portfolio management systems including dashboards and standardized portfolio views/timelines to improve visibility and identify execution and resourcing gaps.
Senior Program Manager at Tessera Therapeutics, USA
August 1, 2021 - June 30, 2022Co-led preclinical programs for rare genetic liver disorders, developing, managing, and tracking integrated plans spanning goals, risk management, and timelines from target ideation through FIH trial initiation. Partnered with non-clinical, CMC, clinical, and regulatory leads to develop integrated program strategies, risk assessments, and cross-functional execution plans. Fostered high-performing collaborative teams by resolving cross-functional conflicts and enabling alignment through strong stakeholder management. Facilitated program and governance meetings by structuring agendas, guiding discussions, challenging assumptions, and enabling data-driven decision-making using the DACI framework. Established portfolio management systems including dashboards and standardized portfolio views/timelines to enhance portfolio visibility and identify execution and resourcing gaps. Provided alliance management support for academic sponsored research agreements (SRAs). Hired, onboarded, and mentor
Senior Associate Program Manager at Editas Medicine, USA
May 1, 2021 - August 31, 2021Co-led early-stage cell therapy programs (oncology, hemoglobinopathies) by developing, managing, and tracking integrated plans across goals, risk management, and timelines from target ideation through development candidate nomination. Managed non-clinical timelines and deliverables for key FDA interactions (1 INteract, 1 pre-IND, 2 IND filings), including building detailed regulatory timelines in collaboration with external consultants. Streamlined research reporting documentation by developing standardized templates, implementing tools, and training users with internal teams and consultants. Supported development of the company's integrated scientific and medical communications strategy with senior leadership and external agencies. Developed executive dashboard templates integrating scientific, operational, and regulatory data to support leadership governance and decision-making forums.
Program Analyst at Editas Medicine, USA
December 1, 2018 - May 31, 2021Co-led early-stage cell therapy programs (oncology, hemoglobinopathies) by developing, managing, and tracking integrated plans across goals, risk management, and timelines from target ideation through development candidate nomination. Managed non-clinical timelines and deliverables for key FDA interactions (1 INteract, 1 pre-IND, 2 IND filings) including building detailed regulatory timelines in collaboration with external consultants. Streamlined research reporting documentation through standardized templates, tools, and user training across internal teams and consultants. Supported development of integrated scientific and medical communications strategy with senior leaders and external agencies. Developed executive dashboard templates integrating scientific, operational, and regulatory datasets to support leadership governance and decision-making forums.
Principal Research Associate at Editas Medicine, USA
March 1, 2017 - December 31, 2017Senior Research Associate at Editas Medicine, USA
September 1, 2014 - February 28, 2017Planned and executed independent scientific experiments for CRISPR platform evolution; presented findings internally and at conferences (ASGCT 2016, Genome Engineering 2018); contributed to publications and patent filings. Supported IND filing through documentation, research report operations, and action item tracking. Managed external collaborations (MIT, UCSF, Genomic Vision) to develop novel off-target assessment approaches. Served as project manager for sequencing submissions and bioinformatics pipeline development. Volunteered for lab operations management during transition periods, including cross-functional facility logistics planning and implementation. Actively contributed to developing company values and fostering an inclusive culture. Trained and mentored new lab members, interns, co-ops, and contractors.
Scientific Associate II at Novartis (NIBR-I)
December 1, 2009 - August 31, 2014Involved in technology development, optimization, preliminary data analysis, and automation of Next Generation Sequencing (NGS) processes using liquid handling robots, along with data management and sample tracking using Laboratory Information Management Systems (LIMS) across multiple programs.
Research Associate II at U.S. Genomics, USA
September 1, 2008 - October 31, 2009Worked on developing an automated system to perform genome sequencing scanning for rapid bacterial strain typing.
Associate Scientist I at Biogen Idec, USA
April 1, 2008 - September 30, 2008Performed microarray expression profiling using Affymetrix/Neurotech technologies and automated liquid handling instruments for internal early discovery and late stage clinical programs.
Intern & Research Associate at MGI Pharma, USA
May 1, 2007 - March 31, 2008Gained experience across discovery and clinical development through rotations involving cell isolation, protein production, drug variability testing, clinical sample analysis, and immune response studies.
at Northeastern University, Dept. of Pharmaceutical Sciences, USA
June 1, 2006 - April 30, 2007Developed a drug delivery system by loading nano-liposome therapeutics into erythrocytes.
Education
Master of Science in Biotechnology - Pharmaceutical Track at Northeastern University, USA
August 1, 2007 - December 31, 2007Bachelor of Engineering - Biomedical at Mumbai University, Thadomal Shahani College of Engineering, India
May 1, 2005 - January 1, 2007Qualifications
Project Management Professional (PMP)
April 1, 2022 - August 25, 2026MassBio Certification - Building and Managing a High Performing Team
June 1, 2023 - August 25, 2026Building Self-Awareness and Improving Personal Effectiveness
October 1, 2020 - August 25, 2026Biotechnology Project Management
October 1, 2019 - August 25, 2026BioTech Primer - Drug Development Immersion Course
December 1, 2018 - August 25, 2026Data Landscape of GenAI for Project Managers
November 1, 2024 - August 25, 2026Talking to AI: Prompt Engineering for Project Managers
November 1, 2024 - August 25, 2026Generative AI Overview for Project Managers
July 1, 2024 - August 25, 2026Industry Experience
Life Sciences, Healthcare, Professional Services, Government
Experience Level
Expert
Expert
Expert
Intermediate
Intermediate
Hire a AI Strategy Consultant
We have the best ai strategy consultant experts on Twine. Hire a ai strategy consultant in Singapore today.